Clinical evaluation of efficacy of dose-modified intravenous busulfan in allogeneic hematopoietic stem cell transplantation for hematological malignancy.
Phase 2
- Conditions
- Hematological malignancy
- Registration Number
- JPRN-UMIN000014077
- Lead Sponsor
- Kyoto University Hospital, Department of Hematology and Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.positive for anti-HIV antibody 2.positive for Hbs antigen 3.active another malignancy 4.uncontrollable psychological disorders 5.uncontrollable active infection 6.positive for donor-specific HLA antibody 7.previous history of hematopoietic stem cell transplantation 8.known hypersensitivity to busulfan 9.pregnant women 10.Patients judged as inappropriate for this study by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method